{"title":"Case Report: Maximizing the anti-proteinuric response: a multicenter real-world sparsentan case series in IgA disorders.","authors":"Abhisekh Sinha Ray, Praveen Errabelli, Maulik Lathiya, Neeharik Mareedu","doi":"10.3389/fneph.2025.1673799","DOIUrl":"10.3389/fneph.2025.1673799","url":null,"abstract":"<p><p>Immunoglobulin A Nephropathy (IgAN) is a prevalent form of glomerulonephritis that leads to chronic kidney disease (CKD), typically marked by ongoing proteinuria, even when treated with standard therapies such as renin-angiotensin-aldosterone system (RAAS) blockers and occasionally immunosuppression. Proteinuria is a modifiable risk factor crucial for disease advancement. Sparsentan, a dual endothelin receptor and angiotensin receptor blocker (DEARA), has been introduced as a novel therapeutic option focusing on proteinuria. We present a case series featuring seven patients - five diagnosed with IgAN and two with IgA vasculitis (IgAV) - with severe proteinuria who were treated with Sparsentan, sometimes in combination with other medications such as targeted-release formulation (TRF) budesonide, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or mycophenolate. Notable reductions in proteinuria and improvements in blood pressure regulation were observed in these cases. Sparsentan was well-tolerated overall, with no significant hyperkalemia or hepatotoxicity reported in this group. These cases emphasize the real-world experience, promising efficacy and safety of Sparsentan in reducing proteinuria in patients with IgA-mediated glomerular disorders, including its application in combination therapies and patients with concurrent or prior immunosuppression.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"5 ","pages":"1673799"},"PeriodicalIF":0.0,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12679704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145703131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Diagnostic agreement and limitations of the Banff automated system in kidney transplant biopsies.","authors":"Jun Matsushita, Toshihito Hirai, Tomokazu Shimizu, Yu Kijima, Kohei Unagami, Masaaki Yanishi, Hidefumi Kinoshita, Toshio Takagi, Hideki Ishida","doi":"10.3389/fneph.2025.1645280","DOIUrl":"10.3389/fneph.2025.1645280","url":null,"abstract":"<p><p>The Banff classification for renal allograft rejection has evolved over time, increasing in complexity. For non-pathologists conducting retrospective studies, assigning Banff diagnostic categories across different eras presents a significant challenge. The Automated Diagnosis System (ADS) is a publicly available web-based tool designed to standardize Banff category diagnoses based on Banff scoring. We retrospectively evaluated ADS using 1,071 kidney biopsy results from 544 transplant recipients, including 146 ABO-incompatible cases performed at our institution. Overall concordance between ADS and pathologists was 69.8%, with high agreement in non-rejection (97.4%) and rejection (86.3%) cases. Among rejection cases, discrepancies were noted in 27 antibody-mediated rejection (AMR) and 22 T cell-mediated rejection (TCMR) cases. Discrepancies were frequently observed in AMR following ABO-incompatible transplantation and in chronic TCMR, highlighting challenges in standardizing these categories. Despite these limitations, ADS demonstrated acceptable concordance and potential utility for promoting global standardization in rejection diagnosis.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"5 ","pages":"1645280"},"PeriodicalIF":0.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12675223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145703171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2025-11-18eCollection Date: 2025-01-01DOI: 10.3389/fneph.2025.1649578
Véronique De Gucht, Dion H A Woestenburg, Vesna Vrecko Pizzulin, Krister Cromm
{"title":"Fatigue and quality of sleep jointly influence the association between physical activity and health-related quality of life in patients with chronic kidney disease: a cross-sectional study.","authors":"Véronique De Gucht, Dion H A Woestenburg, Vesna Vrecko Pizzulin, Krister Cromm","doi":"10.3389/fneph.2025.1649578","DOIUrl":"10.3389/fneph.2025.1649578","url":null,"abstract":"<p><strong>Introduction: </strong>Fatigue is a prevalent and burdensome symptom in Chronic Kidney Disease (CKD), with major impact on Health-Related Quality of Life (HRQoL). Physical activity has been linked to improvements in both fatigue and HRQoL. This study examined whether physical activity relates to HRQoL indirectly through fatigue and whether this relationship is moderated by sleep quality.</p><p><strong>Methods: </strong>A total of 465 CKD patients (mean age = 53.78 years; 50% female) participated in the study. Fatigue, physical activity, HRQoL, and sleep quality were assessed and compared to general population norms and across treatment modalities using t-tests and ANCOVAs. Mediation, moderation, and moderated mediation analyses were conducted.</p><p><strong>Results: </strong>CKD patients reported lower physical activity levels, HRQoL, and sleep quality, and higher fatigue than the general population (all <i>p</i>s <.001). Among treatment groups, transplant recipients showed the most favorable outcomes, while patients without renal replacement therapy reported the poorest. Higher levels of physical activity were associated with better HRQoL indirectly through fatigue, with small to moderate effect sizes. Stronger associations observed in those reporting better sleep quality.</p><p><strong>Discussion: </strong>These findings indicate that physical activity is associated with better HRQoL in CKD patients through its relationship with fatigue, particularly among those with good sleep quality. Future research should explore fatigue across CKD stages to optimize interventions that target both physical activity and sleep.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"5 ","pages":"1649578"},"PeriodicalIF":0.0,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12668941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145672839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Case Report: Focal xanthogranulomatous pyelonephritis in children: diagnostic pitfalls and the role of conservative management.","authors":"Bochra Aziza, Nada Sghairoun, Nader Bennour Ghaddab, Yasmine Houas, Said Jlidi","doi":"10.3389/fneph.2025.1709724","DOIUrl":"10.3389/fneph.2025.1709724","url":null,"abstract":"<p><strong>Background: </strong>Focal xanthogranulomatous pyelonephritis (XGP) is a rare chronic renal inflammatory disorder in children that often mimics renal neoplasms, complicating diagnosis and management.</p><p><strong>Methods: </strong>We describe two pediatric cases of focal XGP managed at our institution and provide a descriptive review of the literature (1975-2024), analyzing clinical presentation, imaging features, management strategies, and outcomes of this disease.</p><p><strong>Results: </strong>Case 1: A 2-year-old boy presented with a febrile right flank mass and systemic inflammation. CT Scan revealed an 80 mm multilocular renal mass. Surgical drainage and biopsy confirmed focal XGP, and targeted antibiotics led to complete resolution with preserved renal function at two-year follow-up. Case 2: A 10-year-old girl presented with a 40 mm left renal mass and systemic inflammatory signs. CT-guided aspiration and histopathology confirmed focal XGP. She was managed conservatively with intravenous and oral antibiotics, achieving complete resolution and normal renal function at seven-year follow-up. Literature review of 34 pediatric XGP cases (median age 11.1 years) showed that 53% were focal lesions. Conservative management with antibiotics, with or without drainage, succeeded in 64% of cases, and overall outcomes were favorable, with stable renal function and no reported mortality.</p><p><strong>Conclusion: </strong>This combined case series and descriptive literature review highlights that conservative, kidney-sparing management is a feasible and effective approach in selected pediatric focal XGP cases. Multicenter collaborations are needed to define standardized diagnostic and therapeutic protocols.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"5 ","pages":"1709724"},"PeriodicalIF":0.0,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12668934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145672803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2025-11-12eCollection Date: 2025-01-01DOI: 10.3389/fneph.2025.1719673
Amir Kazory, Claudio Ronco, Abhilash Koratala
{"title":"Charting the future of cardiorenal medicine: a vision for integration, innovation, and impact.","authors":"Amir Kazory, Claudio Ronco, Abhilash Koratala","doi":"10.3389/fneph.2025.1719673","DOIUrl":"https://doi.org/10.3389/fneph.2025.1719673","url":null,"abstract":"","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"5 ","pages":"1719673"},"PeriodicalIF":0.0,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12646916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145643757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2025-10-27eCollection Date: 2025-01-01DOI: 10.3389/fneph.2025.1630718
William Wilberforce Amoah, Chikaodili Ihudiebube-Splendor, Victor Luckyboy Dzramado
{"title":"Impact of chronic kidney disease on health-related quality of life in adults: a systematic review and meta-analysis protocol.","authors":"William Wilberforce Amoah, Chikaodili Ihudiebube-Splendor, Victor Luckyboy Dzramado","doi":"10.3389/fneph.2025.1630718","DOIUrl":"10.3389/fneph.2025.1630718","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic Kidney Disease (CKD) significantly impacts patients' health-related quality of life (HRQoL), yet comprehensive evidence synthesis remains limited, particularly from African contexts. This systematic review aims to evaluate how CKD affects HRQoL in adult patients and identify the most impacted domains across disease stages, providing evidence to guide patient-centered care and health policy.</p><p><strong>Methods: </strong>Following PRISMA-P 2020 guidelines, we will systematically search PubMed, Embase, Scopus, Web of Science, Cochrane Library, and grey literature for observational studies and clinical trials evaluating HRQoL in adults (≥18 years) with CKD using validated instruments (SF-36, KDQOL, EQ-5D). Two independent reviewers will conduct study selection, data extraction, and quality assessment using the Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool. Meta-analysis will be performed where feasible, with subgroup analyses by CKD stage, treatment modality, and geographic region.</p><p><strong>Expected outcomes: </strong>This review will provide nurses and clinicians with comprehensive evidence on HRQoL impairments across CKD stages, inform development of targeted psychosocial interventions, and guide resource allocation for holistic patient care. Findings will support healthcare providers in addressing not only physiological parameters but also patients' subjective wellbeing and quality of life.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251036629.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"5 ","pages":"1630718"},"PeriodicalIF":0.0,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12597762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145496368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2025-10-23eCollection Date: 2025-01-01DOI: 10.3389/fneph.2025.1647025
J Hernandez-Vaquero, A Repilado-Alvarez, J C de la Flor, T Mata Forte
{"title":"Hemoadsorption: a new tool in neurotoxic poisoning.","authors":"J Hernandez-Vaquero, A Repilado-Alvarez, J C de la Flor, T Mata Forte","doi":"10.3389/fneph.2025.1647025","DOIUrl":"10.3389/fneph.2025.1647025","url":null,"abstract":"<p><p>Although the use of neurotoxic agents as weapons of war (CWAs) or in terrorist attacks is relatively uncommon, it has been documented on several occasions in recent history, including the Syrian civil war, the Tokyo subway attack, and the Salisbury incident. The toxidrome associated with these agents is well described; however, treatment remains largely supportive, as effective antidotes are not currently available. Conventional renal replacement therapies (RRT), such as hemodialysis or continuous modalities, are not recommended for managing neurotoxic agent poisoning due to their toxicodynamic properties. In contrast, hemoadsorption (HA), especially when combined with CRRT, has shown promise in organophosphate (OP) pesticide poisonings. Given the chemical similarities between neurotoxic CWAs and OP, HA may represent a rational therapeutic option in selected cases. Notably, substantial differences exist among these agents in terms of onset of action, routes of exposure, and pharmacodynamics, which critically affect both treatment effectiveness and the availability of a therapeutic window. While the management of such exposures has traditionally fallen under military medical services, documented use in terrorist contexts underscores the importance of civilian healthcare professionals being familiar with current treatment options. This article reviews the pathophysiological mechanisms and key chemical properties of neurotoxic agents and evaluates the potential role of HA as an adjunctive therapy in the management of patients exposed to these CWAs.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"5 ","pages":"1647025"},"PeriodicalIF":0.0,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12588860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145483532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2025-10-22eCollection Date: 2025-01-01DOI: 10.3389/fneph.2025.1671763
R Mohamad Javier, Jonathan Salim, Bethari Lekso Aji, Benardinus Prima Ardjie Pradipta, Choirin Nur, Iqbal Muhammad, Livaldi Naufal Aflah, Immaculata Agata Bornok Rettauli, Cristal Audrey, Irma Wijayaningtyas, Yosua Darmadi Kosen, Adhitya Fajriyadi, Nourma Sabila, Fernando Pangruruk Salipadang, Mahardika Adhitya Nugraha, Nadhira Yuisi Cheda, Andra Purwanto Yogatama Putra, Dhial Falah Mahasin, Mutiara Delia Subiyanto, Arkan Zikri Berlian, Muhamad Zulfikar Hadiaturahman, Ratna Kumala Luthfi, Muhammad Reva Aditya, Hafidha Camila Arif, Kristian Kurniawan
{"title":"Risk factors for chronic kidney disease and septic shock with hypertension in adults and children.","authors":"R Mohamad Javier, Jonathan Salim, Bethari Lekso Aji, Benardinus Prima Ardjie Pradipta, Choirin Nur, Iqbal Muhammad, Livaldi Naufal Aflah, Immaculata Agata Bornok Rettauli, Cristal Audrey, Irma Wijayaningtyas, Yosua Darmadi Kosen, Adhitya Fajriyadi, Nourma Sabila, Fernando Pangruruk Salipadang, Mahardika Adhitya Nugraha, Nadhira Yuisi Cheda, Andra Purwanto Yogatama Putra, Dhial Falah Mahasin, Mutiara Delia Subiyanto, Arkan Zikri Berlian, Muhamad Zulfikar Hadiaturahman, Ratna Kumala Luthfi, Muhammad Reva Aditya, Hafidha Camila Arif, Kristian Kurniawan","doi":"10.3389/fneph.2025.1671763","DOIUrl":"10.3389/fneph.2025.1671763","url":null,"abstract":"<p><strong>Background: </strong>Chronic kidney disease (CKD) affects nearly 10% of the global population and often progresses silently to end-stage renal disease, requiring dialysis or transplantation. Hypertension, prevalent in both adults and children, is a key driver of CKD progression. Acute kidney injury (AKI), particularly sepsis-associated AKI (S-AKI), poses a critical risk for long-term renal dysfunction, especially in patients with pre-existing CKD. S-AKI, defined by abrupt renal function decline during sepsis or septic shock, can accelerate CKD progression, yet its risk factors and outcomes across pediatric and adult populations remain incompletely characterized.</p><p><strong>Objective: </strong>Aims to systematically evaluate existing research on the relationship between Risk Factors for CKD and Septic Shock with Hypertension in Adults and Children.</p><p><strong>Methods: </strong>A systematic literature search was conducted using PubMed, Google Scholar, and the Cochrane Library for studies published between 2004 and 2024. Search terms included \"chronic kidney disease,\" \"septic shock,\" \"hypertension,\" and \"acute kidney injury.\" After applying PRISMA-based screening and eligibility criteria, 9 studies were included for qualitative synthesis.</p><p><strong>Results: </strong>A total of 762 articles were identified through database searching. After screening and eligibility assessment, 9 studies were included in the final synthesis. The findings revealed that both CKD and hypertension are significant independent risk factors for S-AKI and septic shock. Preexisting albuminuria, uncontrolled blood pressure, advanced age, and diabetes mellitus were frequently associated with poor outcomes. Several studies highlighted the role of MPP and fluid resuscitation strategies in preventing AKI progression in septic patients. In pediatric populations, a history of AKI was strongly associated with new-onset hypertension and subsequent CKD development, increasing vulnerability to severe septic complications.</p><p><strong>Conclusion: </strong>CKD and hypertension significantly increase the risk of septic complications and worsen renal outcomes, particularly in patients with fluid management challenges. Early identification of high-risk patients, individualized hemodynamic targets, and tailored fluid resuscitation strategies are critical in reducing morbidity and mortality. Special attention is needed in pediatric patients with limited nephron reserve, where long-term surveillance and early intervention may improve outcomes.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/display_record.php, identifier PROSPERO (CRD420251146866).</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"5 ","pages":"1671763"},"PeriodicalIF":0.0,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12586122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145460817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Global burden, regional disparities, and future projections of hypertensive kidney disease in older adults: analysis of GBD 1990-2021 data.","authors":"Juan Li, Zeyu Jiao, Fang Cheng, Ting Liu, Ruixia Kang, Yongyuan Cai, Ruifang Zhang, Xiaoming Xue","doi":"10.3389/fneph.2025.1656865","DOIUrl":"10.3389/fneph.2025.1656865","url":null,"abstract":"<p><strong>Aims: </strong>Hypertensive kidney disease (HKD) contributes significantly to global morbidity and mortality. This study evaluated the burden of HKD in older adults (≥60 years) across 204 countries from 1990 to 2021 and projected trends to 2045.</p><p><strong>Methods: </strong>Data from the Global Burden of Disease Study 2021 were used to estimate HKD prevalence, incidence, mortality, and disability-adjusted life years (DALYs). Age-standardized rates (ASRs) were calculated with 95% uncertainty intervals (UIs). Temporal trends were analyzed using Joinpoint regression. Slope and concentration indices quantified health inequality. Decomposition and frontier analyses explored burden drivers. Future projections were made using Nordpred-based Bayesian age-period-cohort models. Sensitivity analyses assessed model robustness. Risk-attributable mortality was also estimated.</p><p><strong>Results: </strong>In 2021, global ASRs were 1674.9 (prevalence), 93.4 (incidence), 36.5 (mortality), and 631.1 (DALYs) per 100,000 older adults. High-SDI regions had higher prevalence (ASPR: 1857.8) and incidence (ASIR: 126.5), while low-SDI regions showed higher mortality (ASMR: 58.6) and DALY rates (ASDR: 972.7). Males across all age groups had higher prevalence (e.g. 95 plus: 9109.6 vs. 7031.5 per 100,000). Leading risk factors included low fruit intake (6.98 deaths per 100,000), high sodium, and lead exposure. From 1990-2021, ASIR (AAPC = 0.63%), ASMR (0.99%), and ASDR (0.77%) rose, while ASPR declined (-0.25%). Decomposition attributed burden increases mainly to population growth (72.3%) and aging (6.7%). Frontier analysis revealed substantial room for improvement in middle-SDI countries. Sensitivity analyses confirmed the stability of trend estimates and projections. Forecasts indicate that deaths in adults ≥90 will triple by 2045 (e.g. 95 plus: 75,271 vs. 20,242 in 2021).</p><p><strong>Conclusion: </strong>HKD burden has grown substantially, with persistent geographic and socioeconomic disparities. Effective mitigation requires not only demographic- and region-specific interventions but also improved access to early detection and dietary risk reduction. Integration of kidney care into primary health systems and aging-focused strategies will be crucial to curb future disease escalation.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"5 ","pages":"1656865"},"PeriodicalIF":0.0,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12575384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145433256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2025-10-09eCollection Date: 2025-01-01DOI: 10.3389/fneph.2025.1677030
Farhan Ali Khan, Katherine A Barraclough, Sandawana William Majoni, Sajan Thomas, Wathsala Munasinghe, Asanga Abeyaratne, Robert Carroll
{"title":"Outcomes post kidney transplantation amongst First Nations Australians in the Northern Territory.","authors":"Farhan Ali Khan, Katherine A Barraclough, Sandawana William Majoni, Sajan Thomas, Wathsala Munasinghe, Asanga Abeyaratne, Robert Carroll","doi":"10.3389/fneph.2025.1677030","DOIUrl":"10.3389/fneph.2025.1677030","url":null,"abstract":"<p><strong>Aims: </strong>1)To compare graft and patient survival rates following deceased donor kidney transplantation in Northern Territory (NT) First Nations Australians between 2001-2011 and 2012-2021. 2)To compare transplant outcomes between First Nations and non-Indigenous Australians during 2012-2021. 3)To assess the impact of eplet mismatches and predicted indirectly recognizable HLA epitopes II (PIRCHE) scores on transplant outcomes in First Nations Australians.</p><p><strong>Background: </strong>Despite advancements in transplant outcomes across Australia, uncertainty exists regarding improvements in graft and patient survival rates for NT First Nations Australians. No study has evaluated the impact of molecular matching on post-transplant outcomes for NT First Nations Australians.</p><p><strong>Methods: </strong>We performed a retrospective cohort study involving NT First Nations Australians transplanted between 2001-2021. Participants were divided into two groups: 2001-2011 and 2012-2021. For comparison, we also included non-Indigenous recipients transplanted during the 2012-2021 period. We analyzed graft and patient survival using Kaplan-Meier curves and assessed the association of eplets and PIRCHE scores with graft outcomes and <i>de novo</i> donor specific antibody (dnDSA) formation.</p><p><strong>Results: </strong>Five-year graft and patient survival rates were 46% and 66% in the 2001-2011 cohort compared with 69.7% and 83.1% in the 2012-2021 cohort. For non-Indigenous recipients (2012-2021), 5-year graft and patient survival were 90.5% and 97.6%. Higher eplet mismatch loads and PIRCHE scores were not associated with graft survival, patient survival, or time to rejection among First Nations Australians.</p><p><strong>Conclusion: </strong>Post-transplant outcomes for First Nations Australians have improved considerably, but they remain inferior to non-Indigenous Australians.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"5 ","pages":"1677030"},"PeriodicalIF":0.0,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12545150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145380177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}